Target cells for lithium in different forms within a heterogeneous hepatocarcinoma-29 population


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Liver cancer is an aggressive and heterogeneous human tumor. Lithium compounds block proliferation and induce apoptosis of hepatocarcinoma cells, but cannot cause the death of an entire population of tumor cells. The aim of this study was to reveal morphological types of target cells for different lithium preparations on the basis of their action on hepatocarcinoma-29 cells. The viability of hepatocarcinoma-29 cells was assessed by the MTT test. A dose-dependent decrease in viability was revealed upon addition of native and nanosized lithium carbonate and citrate. Target cells for lithium salts were revealed based on the morphological criteria for five differentiation stages of hepatocarcinoma-29 cells. It was shown that hepatocarcinoma- 29 proliferating cells of differentiation stages I and II are the target cells for native and nanosized lithium citrate, while differentiated cells of differentiation stages III and IV are the target cells for nanosized lithium carbonate. It was revealed that hepatocarcinoma-29 cells are more sensitive to nanosized lithium salts rather than to their native forms. This makes it possible to affect tumor growth more effectively.

About the authors

Yu. S. Gavrilova

Research Institute of Clinical and Experimental Lymphology

Author for correspondence.
Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

N. P. Bgatova

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

A. O. Solov’eva

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

K. E. Trifonova

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

A. P. Lykov

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

Yu. I. Borodin

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

V. I. Konenkov

Research Institute of Clinical and Experimental Lymphology

Email: inabrite@yandex.ru
Russian Federation, ul. Timakova 2, Novosibirsk, 630060

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Pleiades Publishing, Ltd.